Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten) failed. The phase III study was evaluating ...

Shares of Arcus Biosciences, Inc. RCUS, a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility. The ...

Regulus Therapeutics (NASDAQ:RGLS) shares tumbled 24% Wednesday after the biotech company reported results from a study analysis for its ADPKD program and issued a regulatory update. Regulus ...

Delcath Systems (NASDAQ:DCTH) stock jumped 15% Tuesday after the company reported positive results from a retrospective study of its Hepzato Kit in the treatment of patients with liver metastases from ...

A Zepbound injection pen. A study showed the Eli Lilly drug mitigated sleep apnea while helping patients lose weight. (Shelby Knowles/Bloomberg News) A new study is boosting stock in drugmaker Eli ...

In the RESILIENT SMA study, taldefgrobep showed clinically meaningful improvements in motor function at all time points on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did ...

Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study. The drug, called navacaprant, was no better than a ...